Gastric DLBCL: negative H pylori status portends poorer outcomes

  • Cheng Y & al.
  • BMC Cancer
  • 28 Aug 2019

  • curated by Emily Willingham, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Negative Helicobacter pylori status is associated with poorer prognosis in de novo gastric diffuse large B-cell lymphoma (DLBCL).

Why this matters

  • Previous studies have suggested an association between positive H pylori status and less aggressive de novo DLBCL.
  • Citing “limited” previous data, these authors say that their findings offer an opening in the early disease stages, when H pylori status is easily assessed, to identify patients with differential outcomes.

Key results

  • Median follow-up was 52.2 (range, 4-116) months.
  • OS for entire group was 78.7%.
  • Median OS: 96.0 (95% CI, 88.9-103.0) months.
  • Median PFS: 91.8 (95% CI, 83.8-99.7) months.
  • 5-year survival with positive vs negative H pylori status:
    • OS: 89.7% vs 71.8%; P=.033.
    • PFS: 89.3% vs 74.1%; P=.040.
  • Positive H pylori status was significantly associated with better PFS (P=.045) and OS (P=.021) outcomes.
  • Infection status showed associations specifically at stage I or II disease but not at stage IIE or IV.

Study design

  • Retrospective analysis of data for 129 patients (51.2% women; median age, 55 [range, 21-84] years) diagnosed with primary de novo gastric DLBCL, January 2009-May 2016.
  • 49.6% were H pylori negative.
  • Funding: None disclosed.

Limitations

  • Monocentric, retrospective design.
  • Some differential treatments.